# Sensome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sensome

- Industry: Medical Devices & Equipment
- Headquarters: Massy, France
- Website: www.sensome.com
- Total disclosed funding: $17M
- Latest round: Series B (Jan 13, 2020)
- Investors on record: 5

## About

Based in France, Sensome SAS specializes in innovative medical technology, offering advanced solutions like the Clotild® connected guidewire for precise tissue identification in critical conditions such as ischemic stroke.Founded in 2014 and headquartered in Massy, France, Sensome SAS focuses on developing medical devices that enhance patient treatment. The company has successfully navigated four investment rounds, with the latest being a Series B round in July 2024, during which it raised EUR 7.361 mn from investors including Asahi Intecc, BNP Paribas Développement, Idinvest Partners, Kurma Partners, and Partech. The current valuation of the company stands at EUR 31.651 mn. CEO Franz Bozsak leads the company, which has not reported any significant pivots or changes in business strategy since its inception.Sensome has developed the Clotild® connected guidewire, a pioneering medical device that integrates impedance-based micro-sensors and machine learning to identify biological tissues upon contact. This guidewire is primarily used in ischemic stroke treatment but is also applicable in oncology and Peripheral Artery Disease (PAD). Sensome caters to hospitals, healthcare providers, and medical professionals in interventional neuroradiology and cardiology, marketing its products to healthcare systems across Europe and North America.Sensome generates revenue through direct sales of its medical devices, primarily the Clotild® guidewire, to healthcare institutions. These B2B transactions often include bulk purchasing agreements, facilitating acquisition at scaled pricing. The company's revenue is supported by partnerships with healthcare facilities committed to utilizing advanced technologies to enhance patient outcomes.In July 2024, Sensome SAS raised EUR 7.361 mn in a Series B funding round, which aims to expand the company’s market reach. Future growth initiatives include the design and launch of new medical technologies, targeting expansion into additional European and North American markets by the end of 2025. The recent funding will be utilized to support these strategic growth objectives.

## Funding rounds

- Series B, Jan 13, 2020, $8.2M — Idinvest Partners, Partech Partners, Kurma Partners, Asahi Intecc, BNP Paribas Developpement
- Series A, Jun 11, 2018, $5.3M — Idinvest Partners, Partech Partners, Kurma Partners, BNP Paribas Developpement
- Series A, Jul 10, 2017, $3.3M — Idinvest Partners, Partech Partners, Kurma Partners

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A, Series B
- Partech Partners (https://capitalatlas.ai/funds/partech-partners) — Series A, Series B
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series A, Series B
- Asahi Intecc — Series B